Cytokinetics CYTK announces its next round of earnings Thursday. Here is Benzinga's everything-that-matters guide for today's Q4 earnings announcement.
Earnings and Revenue
Sell-side analysts are expecting Cytokinetics's loss per share to be near 70 cents on sales of $6.32 million.
In the same quarter last year, Cytokinetics reported earnings per share of 16 cents per share on revenue of $33.1 million. If the company were to match the consensus estimate when it reports Thursday, EPS would have fallen 537.5 percent. Sales would be down 80.93 percent on a year-over-year basis.
Here's how the Cytokinetics's reported EPS has stacked up against analyst estimates in the past:
| Quarter | Q3 2017 | Q2 2017 | Q1 2017 | Q4 2016 |
| EPS Estimate | -0.61 | -0.59 | -0.27 | -0.4 |
| EPS Actual | -0.6 | -0.6 | -0.62 | 0.16 |
Stock Performance
Over the last 52-week period, shares are down 23.13 percent. Given that these returns are generally negative, long-term shareholders are probably a little upset going into this earnings release.
Analyst estimates are adjusted lower for EPS and revenues over the past 90 days. The popular rating by analysts on Cytokinetics stock is a Neutral. The strength of this rating has maintained conviction over the past 90 days.
Conference Call
Cytokinetics' Q4 conference call is scheduled to begin at 4:00 p.m. ET and can be accessed here: https://cytokinetics.com/
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
